Effect of endocrine therapy on a brain metastatic lesion of prostatic carcinoma.
We describe a 62-year-old male with brain metastasis from prostatic carcinoma, which regressed with medical and surgical endocrine therapies. The patient's presenting complaints were left periocular and deep ocular pain and a defect of the left visual field. During treatment of the above symptoms, macrohematuria, dysuria and pollakiuria occurred. Pathological examination of a transrectal needle biopsy disclosed moderately differentiated adenocarcinoma of the prostate. Computerized tomographic scan (CT) and magnetic resonance imaging demonstrated a brain tumor at the frontal skull base and the region of the frontal lobe suspected to be a metastasis of the prostatic carcinoma. One week after a period of daily administration of estramustine phosphate sodium, the prostate was observed to be softened and slightly decreased in size. The visual field defect and disturbance of urination gradually improved. The prostate decreased to normal size and no tumor mass could be detected on the brain CT after 3 months of treatment.
Kohri
K
K
Department of Urology, Kinki University School of Medicine, Osaka, Japan.
Yamate
T
T
Tsujihashi
H
H
Nakao
Y
Y
Katayama
Y
Y
Hara
Y
Y
Morikawa
Y
Y
Kurita
T
T
D000230:Adenocarcinoma / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy; D001707:Biopsy, Needle; D001932:Brain Neoplasms / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D004961:Estramustine / Q000627:therapeutic use*; D005625:Frontal Lobe; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D010146:Pain / Q000209:etiology; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology*; D014057:Tomography, X-Ray Computed; D014463:Ultrasonography; D014786:Vision Disorders / Q000209:etiology
D004961:Estramustine